BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 26213313)

  • 1. Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma.
    Zegers CM; van Elmpt W; Hoebers FJ; Troost EG; Öllers MC; Mottaghy FM; Lambin P
    Acta Oncol; 2015; 54(9):1378-84. PubMed ID: 26213313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging.
    Zegers CM; van Elmpt W; Reymen B; Even AJ; Troost EG; Ollers MC; Hoebers FJ; Houben RM; Eriksson J; Windhorst AD; Mottaghy FM; De Ruysscher D; Lambin P
    Clin Cancer Res; 2014 Dec; 20(24):6389-97. PubMed ID: 25316821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of tumour hypoxia during radiotherapy using [
    Zegers CM; Hoebers FJ; van Elmpt W; Bons JA; Öllers MC; Troost EG; Eekers D; Balmaekers L; Arts-Pechtold M; Mottaghy FM; Lambin P
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2139-2146. PubMed ID: 27251643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeatability of hypoxia PET imaging using [¹⁸F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial.
    Zegers CM; van Elmpt W; Szardenings K; Kolb H; Waxman A; Subramaniam RM; Moon DH; Brunetti JC; Srinivas SM; Lambin P; Chien D
    Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1840-9. PubMed ID: 26136164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproducibility of (18)F-FDG PET uptake measurements in head and neck squamous cell carcinoma on both PET/CT and PET/MR.
    Rasmussen JH; Fischer BM; Aznar MC; Hansen AE; Vogelius IR; Löfgren J; Andersen FL; Loft A; Kjaer A; Højgaard L; Specht L
    Br J Radiol; 2015 Apr; 88(1048):20140655. PubMed ID: 25634069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT.
    Even AJG; Reymen B; La Fontaine MD; Das M; Jochems A; Mottaghy FM; Belderbos JSA; De Ruysscher D; Lambin P; van Elmpt W
    Acta Oncol; 2017 Nov; 56(11):1591-1596. PubMed ID: 28840770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.
    Wiedenmann N; Bunea H; Rischke HC; Bunea A; Majerus L; Bielak L; Protopopov A; Ludwig U; Büchert M; Stoykow C; Nicolay NH; Weber WA; Mix M; Meyer PT; Hennig J; Bock M; Grosu AL
    Radiat Oncol; 2018 Aug; 13(1):159. PubMed ID: 30157883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ¹⁸F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer.
    Delouya G; Igidbashian L; Houle A; Bélair M; Boucher L; Cohade C; Beaulieu S; Filion EJ; Coulombe G; Hinse M; Martel C; Després P; Nguyen-Tan PF
    Radiother Oncol; 2011 Dec; 101(3):362-8. PubMed ID: 21885143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.
    van Elmpt W; Zegers CML; Reymen B; Even AJG; Dingemans AC; Oellers M; Wildberger JE; Mottaghy FM; Das M; Troost EGC; Lambin P
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):240-248. PubMed ID: 26338178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.
    Zschaeck S; Haase R; Abolmaali N; Perrin R; Stützer K; Appold S; Steinbach J; Kotzerke J; Zips D; Richter C; Gudziol V; Krause M; Zöphel K; Baumann M
    Acta Oncol; 2015; 54(9):1355-63. PubMed ID: 26398663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
    Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation analysis of [
    Di Perri D; Lee JA; Bol A; Hanin FX; Janssens G; Labar D; Robert A; Sterpin E; Geets X
    Acta Oncol; 2017 Sep; 56(9):1181-1188. PubMed ID: 28537761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of [
    Di Perri D; Lee JA; Bol A; Hanin FX; Janssens G; Labar D; Robert A; Sterpin E; Geets X
    Acta Oncol; 2017 Apr; 56(4):516-524. PubMed ID: 28358668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
    Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
    Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of quantitative diffusion-weighted imaging and 18-F-FDG-PET in head and neck squamous cell carcinoma treated by (chemo)radiotherapy.
    Martens RM; Noij DP; Koopman T; Zwezerijnen B; Heymans M; de Jong MC; Hoekstra OS; Vergeer MR; de Bree R; Leemans CR; de Graaf P; Boellaard R; Castelijns JA
    Eur J Radiol; 2019 Apr; 113():39-50. PubMed ID: 30927958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of outcomes with delayed (18)F-FDG PET-CT response assessment in head and neck squamous cell carcinoma.
    Slevin F; Subesinghe M; Ramasamy S; Sen M; Scarsbrook AF; Prestwich RJ
    Br J Radiol; 2015 Aug; 88(1052):20140592. PubMed ID: 26081447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study.
    Rogasch J; Beck M; Stromberger C; Hofheinz F; Ghadjar P; Wust P; Budach V; Amthauer H; Tinhofer I; Furth C; Walter-Rittel TC; Zschaeck S
    F1000Res; 2020; 9():1350. PubMed ID: 33796277
    [No Abstract]   [Full Text] [Related]  

  • 20. 1-[11C]-acetate PET imaging in head and neck cancer--a comparison with 18F-FDG-PET: implications for staging and radiotherapy planning.
    Sun A; Sörensen J; Karlsson M; Turesson I; Langström B; Nilsson P; Cederblad L; Bertling J; Riklund K; Johansson S
    Eur J Nucl Med Mol Imaging; 2007 May; 34(5):651-657. PubMed ID: 17146654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.